BioxyneASX:BXNDA -2.06%50 EBITDA Margin % is 25.75% as of Dec. 2025. GuruFocus rates ASX:BXNDA with a GF Score™ of 50/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,953 Consumer Packaged Goods companies, Bioxyne ranks better than 80.85% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioxyne's EBITDA for the
six
months ended in Dec. 2025 was A$8.06 Mil. Bioxyne's Revenue for the
six
months ended in Dec. 2025 was A$31.31 Mil. Therefore, Bioxyne's EBITDA margin for the quarter that ended in Dec. 2025 was 25.75%.
Bioxyne (ASX:BXNDA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bioxyne EBITDA Margin % Related Terms
Bioxyne EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bioxyne's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Bioxyne's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioxyne EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioxyne's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bioxyne's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioxyne (ASX:BXNDA) has a EBITDA Margin % of 25.75% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioxyne and its competitors. According to the industry distribution chart, Bioxyne ranks #374 out of 1953 companies in the Consumer Packaged Goods industry, placing it in the top 19.2%.
Is Bioxyne's EBITDA Margin % too high?
Bioxyne's current EBITDA Margin % is 25.75%. The Consumer Packaged Goods industry median EBITDA Margin % is 8.99. Bioxyne's value of 25.75% is 186.4% above this industry median. Based on the distribution chart, Bioxyne ranks #374 out of 1953 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Bioxyne has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioxyne's EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Bioxyne ranks #374 out of 1953 companies for EBITDA Margin %. This places Bioxyne in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 8.99. Bioxyne's value of 25.75% is 186.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.99, based on 1,953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioxyne's current EBITDA Margin % of 25.75% is 186.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioxyne and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioxyne's current EBITDA Margin % is 25.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioxyne stock overvalued right now?
Based on GuruFocus' analysis, Bioxyne (ASX:BXNDA) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.95 — trading 37.7% above its estimated fair value. The current EBITDA Margin % is 25.75% and 186.4% above the Consumer Packaged Goods industry median of 8.99. Bioxyne's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioxyne (ASX:BXNDA), the current EBITDA Margin % is 25.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioxyne (ASX:BXNDA) Overvalued in 2026?
Based on GuruFocus' analysis, Bioxyne stock appears to be overvalued.
The current stock price of A$0.95 is trading 37.7% above its estimated GF Value™ of A$0.69.
GuruFocus considers Bioxyne to be Significantly Overvalued.
Key valuation signals for ASX:BXNDA:
EBITDA Margin %: 25.75%
GF Value™: A$0.69 vs. price of A$0.95 (37.7% above fair value)
Industry Position: 186.4% above the Consumer Packaged Goods median (#374 of 1953)
No single metric tells the full story. See the ASX:BXNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
50GF Score
Get the complete analysis for ASX:BXNDA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BXNDA has been successfully added to your 
